Phase 2RecruitingPriority 3 · Moderate priorityNCT06160843
Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma
Plain-language summary
This trial is testing Pembrolizumab IV infusion Q3W for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 21 Years to 99 Years years
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Pembrolizumab IV infusion Q3W, with daily oral Olaparib. (DRUG): Pembrolizumab IV infusion 200 mg Q3W, with daily oral Olaparib 300mg BID, over a 3-week cycle.
Pembrolizumab IV infusion Q3W, with daily oral Olaparib.
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details